With the spiraling amount of time and money needed to bring a drug to market weighing heavy on their Big Pharma clients, CROs have invested in efficiency boosting technology to gain a competitive edge. And the trend is tipped to continue, with an analyst predicting CROs will be at the forefront of developments in IT and genomics in 2014.
PolyTherics and Antitope have completed a merger of their equally sized biopharma services businesses in the U.K., seeking to provide technology and support to the pack of drugmakers in the hunt for biologics such as antibody-drug conjugates.
Another clinical trial search engine rolled out this week with talk of making it easier for patients to find studies, and vice versa. But the website, MyClinicalTrialLocator, finds itself in an increasingly congested market filled with CROs, in-house Big Pharma platforms and niche players.
Mytrus has found a new patron as the startup advances mobile apps for clinical trials. InVentiv Health, a contract research organization (CRO) for pharma and device companies, has snapped up an equity stake in Mytrus and plans to partner on commercializing the startup's mobile apps.
Quintiles made it official on Feb. 15, filing to raise up to $600 million in an IPO after months of rumors and speculation.
Remember those rumors back in January about a big Quintiles IPO? Somebody had some good information. The global CRO filed its S-1 with the SEC this afternoon, outlining plans to go public in one of the biggest new industry offerings in quite some time.
INC Research has signed on to use goBalto's web-based software to boost the process of getting clinical trials up and running, providing the Bay Area startup with what appears to be one of its biggest customer wins yet for the tech.
Piramal Healthcare has accelerated its move into market access modeling by snapping up U.K. firm Abacus International for an undisclosed fee. The takeover comes months after India-based Piramal jumped into the sector by snagging Decision Resources Group for $635 million.
Tigermed Consulting, a CRO based in Shanghai, has opted to use Merge's CTMS for sponsors and CROs to efficiently advance studies.
After chopping deep into its R&D operations to scale back on expenses, AstraZeneca has struck a pact to outsource part of its drug discovery operations to a CRO in China. Pharmaron, which only recently snipped the ribbon at its new complex in Beijing, will play a supporting role on chemistry, drug metabolism and pharmacokinetics, and efficacy screening for the pharma giant in a multi-year deal announced over the weekend.